AstraZeneca reported mixed results across three late-stage lung cancer studies, posting positive Phase 3 data for Tagrisso-Orpathys and Enhertu while discontinuing the eVOLVE-Lung02 trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer. The halted study had enrolled 895 participants across 25 countries and tested volrustomig with chemotherapy as a first-line treatment for patients whose tumors expressed PD-L1 below 50%, with the main analysis centered on those with PD-L1-negative disease. An Independent Data Monitoring Committee concluded during a planned review that the regimen was unlikely to meet its dual primary endpoints of progression-free survival and overall survival in patients with PD-L1 expression below 1%. AstraZeneca said no unexpected safety signals were identified, and the adverse event profile was consistent with the known safety of the individual treatments. In the SAFFRON study, Tagrisso combined with Orpathys significantly improved overall survival and progression-free survival versus platinum-based chemotherapy in patients with EGFR-mutated non-small cell lung cancer whose disease had progressed after earlier Tagrisso treatment and whose tumors showed high MET amplification or overexpression. In DESTINY-Lung04, Enhertu improved progression-free survival over the standard of care as a first treatment for unresectable, locally advanced, or metastatic HER2-mutant non-squamous non-small cell lung cancer. Other Phase 3 volrustomig trials in mesothelioma, cervical cancer, and head and neck squamous cell carcinoma will continue.